Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. (scientific article published on 10 July 2017)

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

Q53607571

The p16INK4a/CDKN2A tumor suppressor and its relatives.

Q54317457

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Q21195212

Fast and accurate short read alignment with Burrows-Wheeler transform

Q24653853

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Q27684731

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Q27860742

Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter

Q28204860

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

Q29547161

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Q29618117

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

Q30426051

mTOR and cancer: many loops in one pathway.

Q33348248

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.

Q33907588

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

Q33952887

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

Q34327021

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.

Q35781547

Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence

Q35805158

Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas

Q36436997

A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model.

Q36786187

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion

Q37420058

Epidemiology of mesothelioma and historical background

Q37863554

Molecular pathogenesis of malignant mesothelioma

Q38107102

Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage.

Q38828447

New therapeutic strategies for malignant pleural mesothelioma

Q38840330

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing

Q38860392

Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations

Q38870695

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones

Q39367929

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.

Q39438194

C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells

Q39954044

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

Q40012079

P433

issue

P921

main subject

malignant pleural mesothelioma

Q18557602

P304

page(s)

637-648

P577

publication date

2017-07-11

P1433

published in

Neoplasia

Q2962042

P1476

title

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells

P478

volume

Reverse relations

cites work (P2860)

Q92890110	Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
Q90643569	CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
Q91767525	CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence
Q64264867	Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
Q94545877	Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
Q89598588	Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response
Q48539535	Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells
Q90088012	Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance
Q92086528	Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer
Q96167066	HOTAIR-EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma
Q57050762	MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report
Q55355075	NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
Q51744108	Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.
Q94464434	Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications
Q64272437	Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
Q55091523	The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
Q60960334	Therapeutic Vulnerabilities in -Mutant AML Unmasked by Palbociclib
Q53697961	Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.

P356	DOI	10.1016/J.NEO.2017.05.003
P932	PMC publication ID	5508477
P698	PubMed publication ID	28704762